Molecular classification and identification of an aggressive signature in low‐grade B‐cell lymphomas

Author:

Hopper Melissa A.1ORCID,Wenzl Kerstin1,Hartert Keenan T.1,Krull Jordan E.1,Dropik Abigail R.1,Novak Joseph P.2,Manske Michelle K.1,Serres MaKayla R.1,Sarangi Vivekananda2,Larson Melissa C.2,Maurer Matthew J.2,Yang Zhi‐Zhang1,Paludo Jonas1ORCID,McPhail Ellen D.1ORCID,Habermann Thomas M.1,Link Brian K.3,Rimsza Lisa M.4,Ansell Stephen M.1,Cerhan James R.2,Jevremovic Dragan5,Novak Anne J.1

Affiliation:

1. Division of Hematology Mayo Clinic Rochester Minnesota USA

2. Department of Quantitative Health Sciences Mayo Clinic Rochester Minnesota USA

3. Division of Hematology, Oncology, and Bone & Marrow Transplantation University of Iowa Iowa City Iowa USA

4. Department of Laboratory Medicine and Pathology Mayo Clinic Phoenix Arizona USA

5. Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA

Abstract

AbstractNon‐follicular low‐grade B‐cell lymphomas (LGBCL) are biologically diverse entities that share clinical and histologic features that make definitive pathologic categorization challenging. While most patients with LGBCL have an indolent course, some experience aggressive disease, highlighting additional heterogeneity across these subtypes. To investigate the potential for shared biology across subtypes, we performed RNA sequencing and applied machine learning approaches that identified five clusters of patients that grouped independently of subtype. One cluster was characterized by inferior outcome, upregulation of cell cycle genes, and increased tumor immune cell content. Integration of whole exome sequencing identified novel LGBCL mutations and enrichment of TNFAIP3 and BCL2 alterations in the poor survival cluster. Building on this, we further refined a transcriptomic signature associated with early clinical failure in two independent cohorts. Taken together, this study identifies unique clusters of LGBCL defined by novel gene expression signatures and immune profiles associated with outcome across diagnostic subtypes.

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3